Boehringer Ingelheim said it presented the analysis of data from two Phase III INPULSIS trials at the 2017 American Thoracic Society (ATS) conference.
The two trials focused the efficacy and safety of using Ofev (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) and showed that the patients treated with Ofev were twice as likely to have improved or stable lung function, versus the patients who took the placebo, Boehringer Ingelheim said in a release.
Idiopathic pulmonary fibrosis is devastating, with a median life expectancy of two to three years. The global INPULSIS-1 and 2 trials treated patients for one year. Those who completed the treatment plus a four week follow-up were offered an extension trial with open-label treatment with Ofev. The ongoing INPULSIS-ON trial has 734 patients enrolled.
“IPF is a progressive disease that requires ongoing treatment," University of Chicago Interstitial Lung Disease Program Director and Professor of Medicine Imre Noth said in the release. "So it is important to assess the long-term efficacy and safety of IPF treatments like Ofev to ensure we are maintaining lung function and reducing disease progression while not exacerbating co-existing conditions. These new data help to further strengthen the science supporting the efficacy and safety of Ofev for up to 96 weeks of treatment and offer physicians additional evidence to support their treatment decisions.”
